nach oben

Erschienen in:

26.08.2020

Caspofungin Effects on Electrocardiogram of Mice: An Evaluation of Cardiac Safety

verfasst von: Danielle Cristiane Correa De Paula, Elaine Amaral Leite, Carolina Morais Araujo, Renata Tupinambá Branquinho, Homero Nogueira Guimarães, Andrea Grabe-Guimarães

Erschienen in: Cardiovascular Toxicology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Caspofungin is an echinocandin, exhibiting efficacy against most Candida species invasive infection. Its cardiotoxicity was reported in isolated rat heart and ventricular myocytes, but in vivo and clinical studies are insufficient. Our objective was to evaluate caspofungin in vivo cardiac effects using an efficacious dose against Candida albicans. Female Swiss mice were infected with C. albicans, and treated with caspofungin, 5 or 10 mg/kg, intraperitoneal along 5 days. Survival rate and colony-forming units (CFU) into vital organs were determined. For cardiac effects study, mice were treated with caspofungin 10 mg/kg, and electrocardiogram (ECG) signal was obtained on C. albicans-infected mice, single dose-treated, and uninfected mice treated along 5 days, both groups to measure ECG intervals. Besides, ECG was also obtained by telemetry on uninfected mice to evaluate heart rate variability (HRV) parameters. The MIC for caspofungin on the wild-type C. albicans SC5314 strain was 0.3 μg/ml, indicating the susceptible. Survival rate increased significantly in infected mice treated with caspofungin compared to mice treated with vehicle. None of the survived infected mice presented positive CFU after treatment with 10 mg/kg. C. albicans infection induced prolongation of QRS, QT, and QTc intervals; caspofungin did not alter this effect. Caspofungin induced increase of PR and an additional increase of QRS after 24 h of a single dose in infected mice. No significant alterations occurred in ECG intervals and HRV parameters of uninfected mice, after caspofungin treatment. Caspofungin showed in vivo cardiac relative safety maintaining its antifungal efficacy against C. albicans.

Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., et al. (2008). In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: Six years of global surveillance. Journal of Clinical Microbiology, 46, 150–156.PubMed

Pappas, P. G., Kauffman, C. A., Andes, D. R., et al. (2016). Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clinical Infectious Disease, 62, 1–50.

Villanueva, A., Arathoon, E. G., Gotuzzo, E., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2001). A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clinical Infectious Diseases, 33, 1529–1535.PubMed

Arathoon, E. G., Gotuzzo, E., Noriega, L. M., et al. (2002). Randomized, double- blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrobial Agents and Chemotherapy, 46, 451–457.PubMedPubMedCentral

Mora-Duarte, J., Betts, R., Rotstein, C., et al. (2002). Caspofungin invasive candidiasis study group. Comparison of caspofungin and amphotericin B for invasive candidiasis. The New England Journal of Medicine, 347, 2020–2029.PubMed

Wang, J. F., Xue, Y., Zhu, X. B., & Fan, H. (2015). Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: A meta-analysis of RCTs. European Journal of Clinical Microbiology & Infectious Disease, 34, 651–659.

Kullberg, B. J., Viscoli, C., Pappas, P. G., et al. (2019). Isavuconazole versus caspofungin in the treatment of candidemia and other invasive candida infections: the ACTIVE trial. Clinical Infectious Disease, 68(12), 1981–1989. https://doi.org/10.1093/cid/ciy827.CrossRef

Sable, C. A., Nguyen, B. Y., Chodakewitz, J. A., & DiNubile, M. J. (2002). Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transplant Infectious Disease, 4, 25–30.PubMed

Klepser, M. E. (2010). Safety and efficacy data for high-dose caspofungin. Current Fungal Infection Reports, 4(2), 59–61. https://doi.org/10.1007/s12281-010-0017-7.CrossRef

10.

Merck Canada Inc. (2017). CANCIDAS^® (caspofungin acetate). Product Monograph. At Health Canada website or Merck Canada website www.merck.ca, 50 pp. https://www.merck.ca/static/pdf/CANCIDAS-PM_E.pdf. Accessed 15 Mar 2020.

11.

Cavero, I., & Crumb, W. (2005). The use of electrocardiograms in clinical trials: A public discussion of the proposed ICH E14 regulatory guidance. Expert Opinion on Drug Safety, 4, 795–799.PubMed

12.

EMEA. European Medicines Agency. (2006). ICH Topic E 14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. At https://www.emea.eu.int, 14 pp. Accessed 10 Dec 2019.

13.

Link, M. G., Yan, G. X., & Kowey, P. R. (2010). Evaluation of toxicity for heart failure therapeutics: studying effects on the QT interval. Circulation Heart Failure, 3(4), 547–555. https://doi.org/10.1161/CIRCHEARTFAILURE.109.917781.CrossRefPubMed

14.

Poluzzi, E., Raschi, E., Motola, D., Moretti, U., & De Ponti, F. (2010). Antimicrobials and the risk of Torsades de Pointes. Drug Safety, 33(4), 303–314.PubMed

15.

Flanagan, S., Goodman, D. B., Jandourek, A., O’Reilly, T., & Sandison, T. (2019). Lack of effect of rezafungin on QT/QTc interval in healthy subjects. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.757.CrossRefPubMed

16.

Ashley, E. S. D., Lewis, R., Lewis, J. S., Martin, C., & Andes, D. (2006). Pharmacology of systemic antifungal agents. Clinical Infectious Diseases, 43(Supplement 1), S28–S39. https://doi.org/10.1086/504492.CrossRef

17.

Philips, J. A., Marty, F. M., Stone, R. M., Koplan, B. A., Katz, J. T., & Baden, L. R. (2007). Torsades de pointes associated with voriconazole use. Transplant Infectious Disease, 9, 33–36.PubMed

18.

Mamtani, S. S., Aljanabi, N., Gupta- Rauniyar, R. P., Acharya, A., & Malik, B. H. (2020). Candida endocarditis: A review of the pathogenesis, morphology, risk factors, and management of an emerging and serious condition. Cureus, 12(1), e6695. https://doi.org/10.7759/cureus.6695.CrossRefPubMedPubMedCentral

19.

Ellis, M. E., Al-Abdely, H., Sandridge, A., Greer, W., & Ventura, W. (2001). Fungal endocarditis: Evidence in the world literature, 1965–1995. Clinical Infectious Disease, 32, 50–62. https://doi.org/10.1086/317550.CrossRef

20.

Aron, A., Manchanda-Aron, U., & Freire, A. X. (2017). Candida endocarditis presenting as acute myocardial infarction. American Journal of Respiratory and Critical Care Medicine, 196(2), e4–e6.PubMed

21.

Landstrom, A. P., Sun, J. J., Ray, R. S., & Wehrens, X. H. T. (2015). It’s not the heart: Autonomic nervous system predisposition to lethal ventricular arrhythmias. Heart Rhythm, 12(11), 2294–2295. https://doi.org/10.1016/j.hrthm.2015.07.008.CrossRefPubMedPubMedCentral

22.

Force, T., & Heart rate variability., (1996). Standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation, 93, 1043–1065.

23.

Stauss, H. M. (2003). Heart rate variability. American Journal of Physiology Regulatory, Integrative and Comparative Physiology, 285, R927–R931.PubMed

24.

Kleiger, R. E., Stein, P. K., & Bigger, J. T., Jr. (2005). Heart rate variability: measurement and clinical utility. Annual Noninvasive Electrocardiology, 10(1), 88–101.

25.

Brateanu, A. (2015). Heart rate variability after myocardial infarction: What we know and what we still need to find out. Current Medical Research Opinion, 31(10), 1855–1860. https://doi.org/10.1185/03007995.2015.1086992.CrossRefPubMed

26.

Lin, W. L., Chen, Y. R., Lai, C. T., Yamada, S., et al. (2018). Neural mechanism of angiotensin-converting enzyme inhibitors in improving heart rate variability and sleep disturbance after myocardial infarction. Sleep Medicine, 48, 61–69. https://doi.org/10.1016/j.sleep.2018.04.007.CrossRefPubMed

27.

McConville, T., Dusek, K., & Dusek, J. (2012). Relaxation response intervention induces respiration and heart rate variability changes in hypertensives. BMC Complement Alternative Medicine, 12, P264. https://doi.org/10.1186/1472-6882-12-S1-P264.CrossRef

28.

Potočnik, N., Perše, M., Cerar, A., Injac, R., & Finderle, Ž. (2017). (2017) Cardiac autonomic modulation induced by doxorubicin in a rodent model of colorectal cancer and the influence of fullerenol pretreatment. PLoS ONE, 12(7), e0181632. https://doi.org/10.1371/journal.pone.0181632.eCollection.CrossRefPubMedPubMedCentral

29.

Hu, T. M., Wu, M. S., Wu, W. T., Yang, F. L., & Lee, R. P. (2016). Selective serotonin reuptake inhibitors increase sympathetic activity under heavy alcohol exposure in rat models. Life Science, 147, 92–96. https://doi.org/10.1016/j.lfs.2016.01.021.CrossRef

30.

Huang, F., Wang, P., Pan, X., Wang, Y., & Ren, S. (2020). Effects of short-term exposure to particulate matters on heart rate variability: A systematic review and meta-analysis based on controlled animal studies. Environmental Pollution, 256, 113306. https://doi.org/10.1016/j.envpol.2019.113306.CrossRefPubMed

31.

Papaioannou, V. E., Dragoumanis, C., Theodorou, V., Gargaretas, C., & Pneumatikos, I. (2009). Relation of heart rate variability to serum levels of C-reactive protein, interleukin 6, and 10 in patients with sepsis and septic shock. Journal Critical Care, 24, 625.e1–7.

32.

Shi, S., Liu, T., Wang, D., et al. (2017). Activation of N-methyl-d-aspartate receptors reduces heart rate variability and facilitates atrial fibrillation in rats. Europace, 19(7), 1237–1243. https://doi.org/10.1093/europace/euw086.CrossRefPubMed

33.

Enoch, D. A., Yang, H., Aliyu, S. H., & Micallef, C. (2017). The changing epidemiology of invasive fungal infections. Methods in Molecular Biology, 1508, 17–65.PubMed

34.

Xin, H., Mohiuddin, F., Tran, J., Adams, A., & Eberle, K. (2019). Experimental mouse models of disseminated Candida auris infection. mSphere. https://doi.org/10.1128/mSphere.00339-19.CrossRefPubMedPubMedCentral

35.

Clinical and Laboratory Standards Institute. (2008). Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard M27-A3, 3rd ed. Clinical and Laboratory Standards Institute, Wayne. https://clsi.org/. Accessed 10 Jan 2016.

36.

Clinical and Laboratory Standards Institute, Wayne, PA. Clinical and Laboratory Standards Institute. (2012). Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard M27-S4, 4rd ed. Clinical and Laboratory Standards Institute, Wayne. https://clsi.org/. Accessed 10 Jan 2016.

37.

Pfaller, M. A., & Diekema, D. J. (2012). Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. Journal Clinical Microbiology, 50, 2846–2856.

38.

Brazilian College of Animal Experimentation—Brazilian Directive for the care and use of animals for scientific and educational purposes. (2013). Colégio Brasileiro de Experimentação Animal COBEA—Diretriz Brasileira para o cuidado e a utilização de animais para fins científicos e didáticos—DBCA). https://www.sbcal.org.br/conteudo/view?ID_CONTEUDO=65.

39.

National Research Council, Eighth Edition. (2011). Guide for the care and use of laboratory animals. National Academy Press. Washington, DC https://www.ncbi.nlm.nih.gov/pubmed/21595115.

40.

Dimopoulou, D., Hamilos, G., Tzardi, M., Lewis, R. E., Samonis, G., & Kontoyiannis, D. P. (2014). Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility. Antimicrobial Agents and Chemotherapy, 58(1), 229–236.PubMedPubMedCentral

41.

Fridericia, L. S. (1920). Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Medica Scandinavica, 53, 469–486.

42.

Speerschneider, T., & Thomsen, M. B. (2013). Physiology and analysis of the electrocardiographic T wave in mice. Acta Physiologica (Oxford), 209(4), 262–271. https://doi.org/10.1111/apha.12172.CrossRef

43.

Vicente, J., Johannesen, L., Hosseini, M., et al. (2016). Electrocardiographic biomarkers for detection of drug-induced late sodium current block. PLoS ONE, 11(12), e0163619. https://doi.org/10.1371/journal.pone.0163619.CrossRefPubMedPubMedCentral

44.

Cesarovic, N., Jirkof, P., Rettich, A., & Arras, M. (2011). Implantation of radiotelemetry transmitters yielding data on ECG, heart rate, core body temperature and activity in free-moving laboratory mice. Journal of Visualized Experiments (JOVE), 57, 1–7.

45.

Shaffer, F., & Ginsberg, J. P. (2017). An overview of heart rate variability metrics and norms. Frontiers in Public Health, 5, 1–17.

46.

Food and Drug Administration, HHS. (2005). International Conference on Harmonisation; guidance on S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT Interval Prolongation) by human pharmaceuticals: availability. Federal Register, 70(202), 133–161.

47.

Shah, R. R., Morganroth, J., & Kleiman, R. B. (2014). ICH E14 document: commentary on the further updated recommendations on thorough QT studies. British Journal Clinical Pharmacology, 79, 456–464.

48.

Farraj, A. K., Hazari, M. S., & Cascio, W. E. (2011). The utility of the small rodent electrocardiogram in toxicology. Toxicology Science, 121, 11–30.

49.

Haverkamp, W., Breithardt, G., Camm, J. A., & Janse, M. J. (2000). The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. European Heart Journal, 47, 219–233.

50.

Fairchild, K. D., Saucerman, J. J., Raynor, L. L., Sivak, J. A., Xiao, Y., Lake, D. E., et al. (2009). Endotoxin depresses heart rate variability in mice: cytokine and steroid effects. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 297, 1019–1027.

51.

Tateishi, Y., Oda, S., Nakamura, M., Watanabe, K., Kuwaki, T., Moriguchi, T., et al. (2007). Depressed heart rate variability is associated with high IL-6 blood level and decline in the blood pressure in septic patients. Shock (Augusta, Ga.), 28, 549–553.

52.

McCarty, T. P., & Pappas, P. G. (2016). Invasive candidiasis. Infectious Disease Clinic of North America, 30, 103–124.

53.

Houšt’, J., Spížek, J., & Havlícek, V. (2020). Antifungal drugs. Review. Metabolites, 10, 106–122. https://doi.org/10.3390/metabo10030106.CrossRef

54.

Wiederhold, N. P., Najvar, L. K., Bocanegra, R. A., Kirkpatrick, W. R., & Patterson, T. F. (2011). Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans. Antimicrobial Agents Chemotherapy, 55, 3254–3260.PubMed

55.

Chen, S. C., Slavin, M. A., & Sorrell, T. C. (2011). Echinocandin antifungal drugs in fungal infections: a comparison. Drugs, 71(1), 11–41. https://doi.org/10.2165/11585270-000000000-00000.CrossRefPubMed

56.

Spreghini, E., Orlando, F., Sanguinetti, M., et al. (2012). Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata. Antimicrobial Agents Chemotherapy, 56, 1215–1222.PubMed

57.

Betts, R. F., Nucci, M., Talwar, D., et al. (2009). A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clinical Infectious Diseases, 48, 1676–1684. https://doi.org/10.1086/598933.CrossRefPubMed

58.

Domán, M., Kovács, R., Perlin, D. S., Kardos, G., Gesztelyi, R., Juhász, B., et al. (2015). Dose escalation studies with caspofungin against Candida glabrata. Journal of Medical Microbiology, 64, 998–1007.PubMedPubMedCentral

59.

Holzschu, D. L., Chandler, F. W., Ajello, L., & Ahearn, D. G. (1979). Evaluation of industrial yeasts for pathogenicity. Sabouraudia, 17, 71–78.PubMed

60.

Chaves, G. M., Cavalcanti, M. A. Q., Carneiro-Leão, A. M. A., & Lopes, L. S. (2004). Model of experimental infection in healthy and immunosuppressed Swiss albino mice (Mus musculus) using Candida albicans strains with different patterns of enzymatic activity. Brazilian Journal of Microbiology, 35, 324–329.

61.

Hajdu, R., Thompson, R., Sundelof, J. G., Pelak, B. A., Bouffard, F. A., Dropinski, J. F., et al. (1997). Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrobial Agents and Chemotherapy, 41, 2339–2344.PubMedPubMedCentral

62.

Kaese, S., & Verheule, S. (2012). Cardiac electrophysiology in mice: a matter of size. Frontiers in Physiology, 345, 1–20.

63.

Victorio, G. B., Bourdon, L. M. B., Benavides, L. G., et al. (2017). Antifungal activity of caspofungin in experimental infective endocarditis caused by Candida albicans. Memórias do Instituto Oswaldo Cruz, 112, 370–375.PubMedPubMedCentral

64.

Holmqvist, F., Thomas, K. L., Broderick, S., et al. (2015). Clinical outcome as a function of the PR-interval-there is virtue in moderation: Data from the Duke Databank for cardiovascular disease. Europace, 17, 978–985.PubMed

65.

Drew, B. J., Ackerman, M. J., Funk, M., et al. (2010). Prevention of Torsade de Pointes In Hospital Settings. A scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation, 121, 1047–1060.PubMedPubMedCentral

66.

Chávez-González, E., Jiménez, A. E. R., & Moreno-Martínez, F. L. (2017). QRS duration and dispersion for predicting ventricular arrhythmias in early stage of acute myocardial infraction. Medicina Intensiva, 41, 347–355. https://doi.org/10.1016/j.medine.2017.04.003.CrossRefPubMed

67.

Zhuo, L., Liu, Q., Liu, L., et al. (2013). Roles of 3,4-methylenedioxymethamphetamine (MDMA)-induced alteration of connexin43 and intracellular Ca²⁺ oscillation in its cardiotoxicity. Toxicology, 310, 61–72. https://doi.org/10.1016/j.tox.2013.05.013.CrossRefPubMed

68.

Jang, S. H., Colangelo, P. M., & Gobburu, J. V. (2010). Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: Evaluating the need to adjust doses based on drug concentrations in plasma. Clinical Pharmacology & Therapeutics, 88, 115–119. https://doi.org/10.1038/clpt.2010.64.CrossRef

69.

Rattanawong, P., Kewcharoen, J., Techorueangwiwat, C., et al. (2019). Wide QRS complex and the risk of major arrhythmic events in Brugada syndrome patients: A systematic review and meta-analysis. Journal of Arrhythmia, 36, 143–152. https://doi.org/10.1002/joa3.12290.CrossRefPubMedPubMedCentral

70.

Lichtenstern, C., Wolff, M., Arens, C., et al. (2013). Cardiac effects of echinocandin preparations—Three case reports. Journal of Clinical Pharmacy and Therapeutics, 38, 429–431.PubMed

71.

Food and Drug Administration. Adverse Events Reporting System (FAERS). (2013). Information/Surveillance/Adverse DrugEffects/ucm082193.htm. www.fda.gov/Drugs/GuidanceComplianceRegulatory. Accessed 30 Jan 2018.

72.

Koch, C., Uhle, F., Wolff, M., et al. (2015). Cardiac effects of echnocandins after central venous administration in adult rats. Antimicrobial Agents and Chemotherapy, 59, 1612–1619.PubMedPubMedCentral

73.

Arens, C., Uhle, F., Wolff, M., et al. (2014). Effects of echinocandin preparations on adult rat ventricular cardiomyocytes. Preliminary results of an in vitro study. Anaesthesist, 63, 129–134. https://doi.org/10.1007/s00101-014-2289-8.CrossRefPubMedPubMedCentral

74.

Lahmer, T., Schnappauf, C., Messer, M., et al. (2015). Influence of echinocandin administration on hemodynamic parameters in medical intensive care unit patients: A single center prospective study. Infection, 43, 723–727.PubMed

75.

Stover, K. R., & Cleary, J. D. (2015). Cardiac response to centrally administered echinocandin antifungals. The Journal of Pharmacy and Pharmacology, 67, 1279–1283.PubMed

76.

Fisch, C. (1973). Relation of electrolyte disturbances to cardiac arrhythmias. Circulation, 47(2), 408–419.PubMed

Titel: Caspofungin Effects on Electrocardiogram of Mice: An Evaluation of Cardiac Safety
verfasst von: Danielle Cristiane Correa De Paula
Elaine Amaral Leite
Carolina Morais Araujo
Renata Tupinambá Branquinho
Homero Nogueira Guimarães
Andrea Grabe-Guimarães
Publikationsdatum: 26.08.2020
Verlag: Springer US
Erschienen in: Cardiovascular Toxicology / Ausgabe 2/2021
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-020-09599-x

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Modulation of the Expression of Long Non-Coding RNAs H19, GAS5, and MIAT by Endurance Exercise in the Hearts of Rats with Myocardial Infarction

Interactive Effects of Omega-3 Polyunsaturated Fatty Acids and Secondhand Smoke in Mice and Human Subjects

Identification of Clinical and Laboratory Variables Associated with Cardiotoxicity Events Due to Doxorubicin in Breast Cancer Patients: A 1-Year Follow-Up Study

Thioredoxin Decreases Anthracycline Cardiotoxicity, But Sensitizes Cancer Cell Apoptosis

Doxorubicin Cytotoxicity in Differentiated H9c2 Cardiomyocytes: Evidence for Acute Mitochondrial Superoxide Generation

Bradykinin-Potentiating Activity of a Gamma-Irradiated Bioactive Fraction Isolated from Scorpion (Leiurus quinquestriatus) Venom in Rats with Doxorubicin-Induced Acute Cardiotoxicity: Favorable Modulation of Oxidative Stress and Inflammatory, Fibrogenic and Apoptotic Pathways